D.E. Shaw & Co
BOLT icon

D.E. Shaw & Co’s Bolt Biotherapeutics BOLT Stock Holding History

D.E. Shaw & Co’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,821
Closed -$74K – 5197
2022
Q2 		$74K Sell
1,821
-13
-0.7% -$505 ﹤0.01% 4779
2022
Q1 		$101K Sell
1,834
-985
-35% -$66.3K ﹤0.01% 4994
2021
Q4 		$276K Sell
2,819
-456
-14% -$86.6K ﹤0.01% 4720
2021
Q3 		$829K Buy
3,275
+2,421
+283% +$684K ﹤0.01% 3754
2021
Q2 		$264K Buy
+854
New +$347K ﹤0.01% 4331

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

D.E. Shaw & Co's BOLT Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 1,821 shares — an estimated $74K sold.

D.E. Shaw & Co first reported a position in BOLT in Q2 2021 and held it in 5 quarters. The position peaked at $829K in Q3 2021. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,821 Bolt Biotherapeutics shares in Q3 2022, an estimated $74K.
  • D.E. Shaw & Co first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Bolt Biotherapeutics position peaked at $829K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.